000			01524 a2200397 4500
005			20250514000016.0
264		0	_c20010913
008			200109s 0 0 eng d
022			_a0148-396X
024	7		_a10.1097/00006123-200105000-00013 _2doi
040			_aNLM _beng _cNLM
100	1		_aKraemer, D F
245	0	0	_aAssociation of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. _h[electronic resource]
260			_bNeurosurgery _cMay 2001
300			_a1033-40; discussion 1040-1 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBlood-Brain Barrier
650	0	4	_aCentral Nervous System Neoplasms _xdrug therapy
650	0	4	_aCohort Studies
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInjections, Intra-Arterial
650	0	4	_aLymphoma _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultivariate Analysis
650	0	4	_aProportional Hazards Models
650	0	4	_aSurvival Analysis
700	1		_aFortin, D
700	1		_aDoolittle, N D
700	1		_aNeuwelt, E A
773	0		_tNeurosurgery _gvol. 48 _gno. 5 _gp. 1033-40; discussion 1040-1
856	4	0	_uhttps://doi.org/10.1097/00006123-200105000-00013 _zAvailable from publisher's website
999			_c11267953 _d11267953